MINNEAPOLIS, May 2, 2014 (GLOBE NEWSWIRE) -- Manny Villafaña, Chairman and CEO of Kips Bay Medical, Inc. (Nasdaq:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS® Mesh, for use in coronary artery bypass grafting surgery, announced today that Kips Bay will release operating and financial results for the first quarter ended March 29, 2014 prior to the open of the regular trading market on Thursday, May 8, 2014. Villafaña also announced that Kips Bay will hold a conference call to discuss its recent business developments at 9:00 A.M. Eastern Time / 8:00 A.M. Central Time on Tuesday, May 13, 2014.
The call can be accessed in the following ways:
-
By the internet: For "listen-only" participants, click on the link in the Investors section of the Kips Bay's website: www.KipsBayMedical.com.
-
By telephone: For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 888-680-0869. For participants outside the U.S., the dial-in number is 617-213-4854. The access code for all callers is 34387971.
- Through an audio replay: A replay of the conference call will be available beginning at 1:00 P.M. on May 13, 2014 and ending at 11:59 P.M. on May 20, 2014. The dial-in number for U.S. participants is 888-286-8010. For participants outside the U.S., the replay dial-in number is 617-801-6888. The replay access code for all callers is 52012914.
About Kips Bay Medical
Kips Bay Medical, Inc., founded in 2007 and headquartered in Minneapolis, Minnesota, is a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, or eSVS® MESH, for use in coronary artery bypass grafting, or CABG, surgery. The eSVS Mesh is designed to be fitted like a sleeve on the outside of saphenous vein grafts, or SVGs, to strengthen SVGs used in coronary artery bypass graft surgery. By strengthening the SVG and preventing the damaging expansion of the vein graft, the Company hopes to reduce or prevent the resulting injury which can lead to SVG failure and potentially costly and complicated re-interventions for patients undergoing CABG surgery. Additional information about Kips Bay Medical, Inc. can be found at www.KipsBayMedical.com.